The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value
Abstract
Two hundred and twelve archival bladder‐cancer biopsy specimens were analyzed immunohistochemically to detect over‐expression of p53 protein. The results of immunohistochemical analysis were correlated to established histological and quantitative prognostic factors and survival of patients during a mean follow‐up period of more than 10 years. Twentynine percent of tumours were positive for p53 protein, and over‐expression was associated with high histological grade, non‐papillary growth architecture, dense inflammatory cell reaction, DNA aneuploidy, high S‐phase fraction, high mitotic frequency and high SD of nuclear area. Progression in T, N and M categories was significantly related to over‐expression of p53 protein. In univariate survival analysis, over‐expression of p53 predicted poor outcome in the entire cohort, in papillary tumours and in muscle‐invasive tumours but not in superficial tumours. In a multivariate survival analysis, over‐expression of p53 oncoprotein had no independent prognostic value over clinical stage and mitotic index. The results confirm that p53 is involved in the growth regulation of bladder cancer and is certainly a subject for detailed analysis of specific mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ
Bravo, R., Frank, R., Blundell, P. A., & Macdonald-Bravo, H. (1987) · Nature · doi:10.1038/326515a0 · Cited by 1,740
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
TNM Classification of Malignant Tumours.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-1-248_1 · Cited by 1,094
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R., Bartek, J., Lane, D., Gatter, K., Harris, A. L., & Bartek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,031
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., et al. (1991) · Science · doi:10.1126/science.2024123 · Cited by 875
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
A computer program for comparing K samples with right-censored data
Lee, E. T., & Desu, M. M. (1972) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(72)90019-0 · Cited by 705
Localization of gene for human p53 tumour antigen to band 17p13
Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986) · Nature · doi:10.1038/320084a0 · Cited by 485
Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300404 · Cited by 450
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
Barton, C., Staddon, S., Hughes, C., Hall, P., O'Sullivan, C., Klöppel, G., Theis, B., Russell, R., Neoptolemos, J., & Williamson, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.467 · Cited by 376
p53 expression and prognosis in gastric carcinoma
Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., & Silvestre, F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500604 · Cited by 321
Mercer, W. E., Shields, M. T., Lin, D., Appella, E., & Ullrich, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1958 · Cited by 249
p53 in colorectal cancer: clinicopathological correlation and prognostic significance
Scott, N., Sagar, P., Stewart, J., Blair, G., Dixon, M., & Quirke, P. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.74 · Cited by 212
When the products of oncogenes and anti-oncogenes meet
Green, M. R. (1989) · Cell · doi:10.1016/0092-8674(89)90975-6 · Cited by 198
Ostrowski, J. L., Sawan, A., Henry, L., Wright, C., Henry, J. A., Hennessy, C., Lennard, T. J. W., Angus, B., & Horne, C. H. W. (1991) · The Journal of Pathology · doi:10.1002/path.1711640113 · Cited by 180
Evaluation of epidermal growth factor receptors in bladder tumours
Berger, M., Greenfield, C., Gullick, W., Haley, J., Downward, J., Neal, D., Harris, A., & Waterfield, M. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.238 · Cited by 165
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Hw, S., Maimets, T., Chumakov, P. M., Brain, R., Addison, C. M., Simanis, V., Rudge, K., Philp, R. J., Grimaldi, M., & Court, W. J. (1990) · PubMed · Cited by 155
Expression of p53 protein in infiltrating and in‐situ breast carcinomas
Walker, R. A., Dearing, S. J., Lane, D. P., & Varley, J. M. (1991) · The Journal of Pathology · doi:10.1002/path.1711650303 · Cited by 152
Thompson, A. M., Anderson, T. J., Condie, A., Prosser, J., Chetty, U., Carter, D. C., Evans, H. J., & Steel, C. M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500405 · Cited by 147
Lipponen, P., Eskelinen, M. J., Jauhiainen, K., Harju, E., & Terho, R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90579-5 · Cited by 139
Self-citationLipponen, P., & Eskelinen, M. J. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.237 · Cited by 87
Self-citation
Cited by
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70315-6 · Cited by 317
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
STEIN, J. P., GROSSFELD, G. D., GINSBERG, D. A., ESRIG, D., FREEMAN, J. A., FIGUEROA, A. J., SKINNER, D. G., & COTE, R. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62747-2 · Cited by 271
Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., & Scher, H. I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1384 · Cited by 254
Metadata
- Authors
- Lipponen, P. K.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1993-02
- Volume
- 53
- Issue
- 3
- Pages
- 365-370
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2155877820
- Cited by
- 253
- References
- 26
- FWCI
- 31.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.